Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Dig Dis ; 36(3): 218-227, 2018.
Article in English | MEDLINE | ID: mdl-29316565

ABSTRACT

BACKGROUND AND AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is the treatment of choice in decompensated portal hypertension. TIPS revision due to thrombosis or stenosis increases morbidity and mortality. Our aim was to investigate patient- and procedure-associated risk factors for TIPS-revision. PATIENTS AND METHODS: We retrospectively evaluated 189 patients who underwent the TIPS procedure. Only patients who required TIPS revision within 1 year (Group I, 34 patients) and patients who did not require re-intervention within the first year (Group II [control group], 54 patients) were included. RESULTS: Out of 88 patients, the majority were male (69.3%) and mean age was 56 ± 11 years. Indications for TIPS were refractory ascites (68%), bleeding (24%), and Budd-Chiari syndrome (8%). The most frequent liver disease was alcohol-induced cirrhosis (60%). Forty-three patients (49%) received bare and 45 patients (51%) covered stents, thus resulting in reduction of hepatic venous pressure gradient (HVPG) from 19.0 to 9.0 mm Hg. When comparing patient- and procedure-related factors, the type of stent (p < 0.01) and interventionalist's experience (number of performed TIPS implantations per year; p < 0.05) were the only factors affecting the risk of re-intervention due to stent dysfunction, while age, gender, indication, Child-Pugh, and model of end-stage liver disease score, platelet count, pre- and post-HVPG, additional variceal embolization, stent diameter, and number of stents did not significantly differ. CONCLUSION: Patients undergoing TIPS procedure should be surveilled closely for shunt dysfunction while covered stents and high-level experience are associated with increased -patency.


Subject(s)
Hypertension, Portal/physiopathology , Hypertension, Portal/therapy , Portasystemic Shunt, Transjugular Intrahepatic , Vascular Patency , Ascites/pathology , Female , Humans , Male , Middle Aged , Retrospective Studies , Stents , Treatment Outcome
2.
Liver Int ; 37(4): 562-568, 2017 04.
Article in English | MEDLINE | ID: mdl-27634287

ABSTRACT

BACKGROUND & AIMS: Patients with progressive liver disease exhibit complex coagulation disorders. Factor XIII plays a crucial role in the last steps of haemostasis, and its deficiency is associated with an increased incidence of bleeding diathesis. However, current conventional coagulation tests cannot detect factor XIII deficiency. In this study, we examined factor XIII activity and the ability of rotational thromboelastometry to detect factor XIII deficiency and bleeding diathesis in patients with cirrhosis. METHODS: We retrospectively studied 74 patients with cirrhosis, comparing the results of conventional coagulation tests (international normalized ratio, activated partial thromboplastin time, platelet count, fibrinogen level), rotational thromboelastometry, factor XIII activity and clinical scores. RESULTS: Patients with cirrhosis exhibited reduced factor XIII activity. Factor XIII activity was positively correlated with conventional coagulation parameters and rotational thromboelastometry values, such as maximum clot formation (MCF)extem (r=.48, P<.0001) and MCFfibtem (r=.60, P<.0001). However, maximum lysis (ML)extem and MLaptem were not correlated with factor XIII activity. Three-month mortality rates (P=.0469) and bleeding complications (P<.0001) were significantly associated with lower factor XIII activity. Patients with haemorrhage exhibited significantly altered rotational thromboelastometry values. CONCLUSIONS: Reduced levels of MCFextem and MCFfibtem but not high levels of MLextem and MLaptem are associated with factor XIII deficiency in patients with liver disease. Therefore, substituting factor XIII should be considered for such patients to strengthen clot formation in patients experiencing haemorrhage or those who have undergone interventions.


Subject(s)
Disease Susceptibility , Factor XIII Deficiency/diagnosis , Liver Cirrhosis/complications , Thrombelastography/methods , Factor XIII Deficiency/etiology , Female , Germany , Hemorrhage/etiology , Humans , International Normalized Ratio , Male , Middle Aged , Platelet Count , Predictive Value of Tests , Retrospective Studies
3.
Digestion ; 90(4): 240-7, 2014.
Article in English | MEDLINE | ID: mdl-25531058

ABSTRACT

BACKGROUND/AIMS: For diagnosis, prognosis, and treatment of acute liver failure (ALF), macroscopic evaluation and histological assessment of the liver are important. Due to impaired coagulation in ALF, the risk of bleeding is high after a percutaneous liver biopsy. Our aims were to assess (i) safety and benefit of mini laparoscopy (ML) in patients with ALF and (ii) the potential utility of histological markers in ALF prognosis. METHODS: ML was performed in 39 patients with ALF to assess liver surface and to obtain a liver biopsy. Serological markers of liver injury and immunohistochemical detection of cell death and proliferation were compared to a non-ALF group (n = 10). RESULTS: Liver biopsies were successfully performed in all patients with no significant complications. All patients had markedly elevated M30 and M65 levels in the serum. In the liver, M30 and Ki67 immune-reactive cells were more abundant in those with ALF. Importantly, there were significantly more Ki67-positive cells but fewer M30-positive cells in livers of ALF patients who recovered spontaneously. CONCLUSION: ML with liver biopsy in patients with ALF and severe coagulopathy is safe. Immunohistochemical detection of liver cell death and regeneration may identify individuals who would recover spontaneously or who would need a liver transplant.


Subject(s)
Biopsy/methods , Blood Coagulation Disorders/etiology , Liver Failure, Acute/diagnosis , Liver/pathology , Adult , Aged , Case-Control Studies , Female , Humans , Keratin-18/metabolism , Ki-67 Antigen/metabolism , Laparoscopy/methods , Liver/metabolism , Liver Failure, Acute/complications , Liver Failure, Acute/surgery , Liver Transplantation , Male , Middle Aged , Peptide Fragments/metabolism , Prognosis , Remission, Spontaneous , Young Adult
4.
Dtsch Med Wochenschr ; 140(14): 1083-90; quiz 1091-2, 2015 Jul.
Article in German | MEDLINE | ID: mdl-26182259

ABSTRACT

Portal hypertension occurs frequently in advanced liver cirrhosis and accounts for the majority of lethal complications. Compensatory splanchnic vasodilation and counter regulatory mechanisms (e.g. activation of the renin-angiotensin-aldosterone system) increase renal vascular resistance, which may facilitate acute kidney injury and the development of hepatorenal syndrome (HRS). HRS represents a functional, yet reversible renal impairment with elevated serum creatinine levels. Establishing the diagnosis, fluid challenge test and several investigations are needed to exclude acute kidney injury and other causes of renal failure. Early treatment with albumin and vasoconstrictors improves the prognosis of HRS patients. The only curative treatment of HRS so far is improvement of liver function implying liver transplantation in many cases. TIPS placement may be useful as a bridging tool to transplantation unless hepatic encephalopathy is present. Spontaneous bacterial peritonitis (SBP) is a relevant, independent risk factor for HRS. In patients with liver cirrhosis and SBP in addition to antibiotics, preventive albumin treatment is recommended.


Subject(s)
Hypertension, Portal/diagnosis , Hypertension, Portal/therapy , Liver Cirrhosis/diagnosis , Liver Cirrhosis/therapy , Renal Insufficiency/diagnosis , Renal Insufficiency/therapy , Combined Modality Therapy/methods , Diagnosis, Differential , Evidence-Based Medicine , Humans , Syndrome , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL